復星國際(00656.HK)及復星醫藥(02196.HK)附屬收購及增資疫苗研發生產業務公司
復星國際(00656.HK)及復星醫藥(02196.HK)聯合公佈,兩者附屬復星醫藥產業與各出售股東,包括金康瑞、上海禾實、趙光輝、薛平、王巖、楊冬妮、楊傑、王霄及馮晨分別訂立股權轉讓協議,復星醫藥產業以11.08億元人民幣(下同)收購成都安特金生物技術合共32.52%持股。
另外,復星醫藥產業並與成都安特金生物技術及其現有股東,包括成都傑弗瑞、趙光輝、楊冬妮、薛平、王巖、楊傑、王霄、趙雪、馮晨、景旭投資、創新創業基金、林國春、上海禾實、奧普尹索及中金康瑞訂立增資協議,復星醫藥產業擬透過附屬雅立峯的100%股權作價28.98億元,認購成都安特金生物技術新增註冊資本4,795.86萬元,佔增資事項完成後成都安特金生物技術經擴大股權總額的60%。
上述交易完成後,復星醫藥產業將持有成都安特金生物技術擴大後股本的73.01%,併成復星國際及復星醫藥附屬。復星醫藥產業將透過成都安特金生物技術續持有雅立峯100%持股。
另外,復星醫藥產業向出售選擇權持有者出具若幹承諾函,據此,復星醫藥產業分別向各出售選擇權持有者授予一項出售選擇權,根據承諾函所列的若幹條件,於增資協議項下交易完成後但不遲於2026年12月31日,出售選擇權持有者均有權要求復星醫藥產業購買其各自屆時持有的合計不超過收購事項完成後約18.8%的成都安特金生物技術股權。
公告指,成都安特金生物技術擁有獨特的多糖-蛋白多價結合專利技術的疫苗研發生產企業,專注於細菌性疫苗的研發。其具有自主知識產權的13價肺炎球菌多價結合疫苗即將開展III期臨牀試驗、24價肺炎球菌多價結合疫苗即將開展I期臨牀試驗,同時正積極佈局ACHib結合型流腦疫苗等產品的研發。成都安特金生物技術在細菌性疫苗的研發能力和產品儲備方面與雅立峯的病毒性疫苗產品線可形成互補和協同。收購及增資事項完成後,有利於強化復星醫藥集團疫苗業務的研發能力和後續產品儲備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.